<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hanne Debergh</style></author><author><style face="normal" font="default" size="100%">Pierre Becker</style></author><author><style face="normal" font="default" size="100%">Vercammen, Francis</style></author><author><style face="normal" font="default" size="100%">Lagrou, Katrien</style></author><author><style face="normal" font="default" size="100%">Roel Haesendonck</style></author><author><style face="normal" font="default" size="100%">Saegerman, Claude</style></author><author><style face="normal" font="default" size="100%">Ann Packeu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary Aspergillosis in Humboldt Penguins—Susceptibility Patterns and Molecular Epidemiology of Clinical and Environmental Aspergillus fumigatus Isolates from a Belgian Zoo, 2017–2022</style></title><secondary-title><style face="normal" font="default" size="100%">Antibiotics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-03-2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">3</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hanne Debergh</style></author><author><style face="normal" font="default" size="100%">Pierre Becker</style></author><author><style face="normal" font="default" size="100%">Vercammen,F.</style></author><author><style face="normal" font="default" size="100%">K. Lagrou</style></author><author><style face="normal" font="default" size="100%">Roel Haesendonck</style></author><author><style face="normal" font="default" size="100%">Saegerman,C.</style></author><author><style face="normal" font="default" size="100%">Ann Packeu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pulmonary Aspergillosis in Humboldt Penguins—Susceptibility Patterns andMolecular Epidemiology of Clinical and Environmental Aspergillus fumigatus Isolates from a Belgian Zoo</style></title><secondary-title><style face="normal" font="default" size="100%">Antibiotics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antifungal susceptibility testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillus fumigatus</style></keyword><keyword><style  face="normal" font="default" size="100%">avian aspergillosis</style></keyword><keyword><style  face="normal" font="default" size="100%">azole resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">cyp51A</style></keyword><keyword><style  face="normal" font="default" size="100%">genotyping</style></keyword><keyword><style  face="normal" font="default" size="100%">MIC</style></keyword><keyword><style  face="normal" font="default" size="100%">microsatellite typing</style></keyword><keyword><style  face="normal" font="default" size="100%">One Health</style></keyword><keyword><style  face="normal" font="default" size="100%">Spheniscus humboldti</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">15/03/2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Aspergillus fumigatus&amp;nbsp;is the main causative agent of avian aspergillosis and results in significant health problems in birds, especially those living in captivity. The fungal contamination by&amp;nbsp;A. fumigatus&amp;nbsp;in the environment of Humboldt penguins (Spheniscus humboldti), located in a Belgian zoo, was assessed through the analysis of air, water, sand and nest samples during four non-consecutive days in 2021–2022. From these samples, potential azole-resistant&amp;nbsp;A. fumigatus&amp;nbsp;(ARAF) isolates were detected using a selective culture medium. A total of 28 veterinary isolates obtained after necropsy of Humboldt penguins and other avian species from the zoo were also included. All veterinary and suspected ARAF isolates from the environment were characterized for their azole-resistance profile by broth microdilution. Isolates displaying phenotypic resistance against at least one medical azole were systematically screened for mutations in the&amp;nbsp;cyp51A&amp;nbsp;gene. A total of 14 (13.6%) ARAF isolates were identified from the environment (n&amp;nbsp;= 8) and from Humboldt penguins (n&amp;nbsp;= 6). The TR34/L98H mutation was observed in all resistant environmental strains, and in two resistant veterinary strains. To the best of our knowledge, this is the first description of this mutation in&amp;nbsp;A. fumigatus&amp;nbsp;isolates from Humboldt penguins. During the period 2017–2022, pulmonary aspergillosis was confirmed in 51 necropsied penguins, which reflects a death rate due to aspergillosis of 68.0%, mostly affecting adults. Microsatellite polymorphism analysis revealed a high level of diversity among environmental and veterinary&amp;nbsp;A. fumigatus&amp;nbsp;isolates. However, a cluster was observed between one veterinary isolate and six environmental strains, all resistant to medical azoles. In conclusion, the environment of the Humboldt penguins is a potential contamination source of ARAF, making their management even more complex.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lorenzo Canti</style></author><author><style face="normal" font="default" size="100%">Grégory Ehx</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Stéphanie Humblet-Baron</style></author><author><style face="normal" font="default" size="100%">Heyndrickx, Leo</style></author><author><style face="normal" font="default" size="100%">Aurélie Henry</style></author><author><style face="normal" font="default" size="100%">Sophie Servais</style></author><author><style face="normal" font="default" size="100%">Evelyne Willems</style></author><author><style face="normal" font="default" size="100%">Stanislas Goriely</style></author><author><style face="normal" font="default" size="100%">Laurence Seidel</style></author><author><style face="normal" font="default" size="100%">Johan Michiels</style></author><author><style face="normal" font="default" size="100%">Betty Willems</style></author><author><style face="normal" font="default" size="100%">Yves Beguin</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author><author><style face="normal" font="default" size="100%">Frédéric Baron</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients.</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Cell</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibody Formation</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Apr 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">40</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">4</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yana Debie</style></author><author><style face="normal" font="default" size="100%">Timon Vandamme</style></author><author><style face="normal" font="default" size="100%">Peeters, Marc</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Maria Goossens</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Peter A van Dam</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Cancer</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Humoral</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunization Schedule</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunization, Secondary</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunogenicity, Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Time Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">163</style></volume><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marta Romano</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Marcel Joniau</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Huygen, Kris</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A BRIEF HISTORY OF BELGIAN IMMUNOLOGY AND ITS SOCIETY.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Immunol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Allergy and Immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Societies, Medical</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">52</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">7</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helen J Esser</style></author><author><style face="normal" font="default" size="100%">Stephanie M Lim</style></author><author><style face="normal" font="default" size="100%">de Vries, Ankje</style></author><author><style face="normal" font="default" size="100%">Sprong, Hein</style></author><author><style face="normal" font="default" size="100%">Dinant J Dekker</style></author><author><style face="normal" font="default" size="100%">Emily L Pascoe</style></author><author><style face="normal" font="default" size="100%">Julian W Bakker</style></author><author><style face="normal" font="default" size="100%">Vanessa Suin</style></author><author><style face="normal" font="default" size="100%">Franz, Eelco</style></author><author><style face="normal" font="default" size="100%">Martina E E Byron</style></author><author><style face="normal" font="default" size="100%">Constantianus J M Koenraadt</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Continued Circulation of Tick-Borne Encephalitis Virus Variants and Detection of Novel Transmission Foci, the Netherlands.</style></title><secondary-title><style face="normal" font="default" size="100%">Emerg Infect Dis</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Encephalitis Viruses, Tick-Borne</style></keyword><keyword><style  face="normal" font="default" size="100%">Encephalitis, Tick-Borne</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Ixodes</style></keyword><keyword><style  face="normal" font="default" size="100%">Netherlands</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">28</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Tick-borne encephalitis virus (TBEV) is an emerging pathogen that was first detected in ticks and humans in the Netherlands in 2015 (ticks) and 2016 (humans). To learn more about its distribution and prevalence in the Netherlands, we conducted large-scale surveillance in ticks and rodents during August 2018-September 2020. We tested 320 wild rodents and &amp;gt;46,000 ticks from 48 locations considered to be at high risk for TBEV circulation. We found TBEV RNA in 3 rodents (0.9%) and 7 tick pools (minimum infection rate 0.02%) from 5 geographically distinct foci. Phylogenetic analyses indicated that 3 different variants of the TBEV-Eu subtype circulate in the Netherlands, suggesting multiple independent introductions. Combined with recent human cases outside known TBEV hotspots, our data demonstrate that the distribution of TBEV in the Netherlands is more widespread than previously thought.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Debby Thomas</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Doreen Dillaerts</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Maaike Cockx</style></author><author><style face="normal" font="default" size="100%">Louanne Ampofo</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Joseph She</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Geukens, Nick</style></author><author><style face="normal" font="default" size="100%">Bossuyt, Xavier</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Development and validation of a microfluidic multiplex immunoassay for the determination of levels and avidity of serum antibodies to tetanus, diphtheria and pertussis antigens.</style></title><secondary-title><style face="normal" font="default" size="100%">J Immunol Methods</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibodies, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Bordetella pertussis</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoassay</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Microfluidics</style></keyword><keyword><style  face="normal" font="default" size="100%">Pertussis Toxin</style></keyword><keyword><style  face="normal" font="default" size="100%">Tetanus</style></keyword><keyword><style  face="normal" font="default" size="100%">Whooping Cough</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">503</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A multiplex assay for the quantitation of immunoglobulin G (IgG) serum antibodies directed against Clostridium tetani toxin (TT), Corynebacterium diphtheriae toxoid (DTxd), and the Bordetella pertussis antigens pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn) was developed on an Evalution® platform to enhance the evaluation of the specific antibody response towards protein antigens in suspected humoral immunodeficiencies. Evalution® is a microfluidic and microparticle-based platform with the possibility to analyse single samples and to perform real-time kinetic measurements of antibody binding. All individual antigens were covalently linked to the carboxylated microparticles after which samples and fluorescently labelled detection antibodies were flowed over the microparticles in the microfluidic channels of the assay cartridges of the system. The developed assay showed very good sensitivity, specificity, and intra- and inter-assay coefficients of variation (CVs for the different antigens between 1.72-3.53% and 3.54-5.79%, respectively). Furthermore, the correlation of the Evalution pentaplex with a Luminex pentaplex using a panel of 48 human serum samples was excellent, with Spearman correlation coefficients between 0.936 for PT and 0.982 for DTxd (p&amp;nbsp;&amp;lt;&amp;nbsp;0.0001 for all). Finally, we showed in a proof-of-concept experiment the potential of the Evalution® platform to simultaneously measure concentrations and binding kinetics (as a surrogate for avidity) of the IgG antibodies to the selected protein antigens. Overall, these findings show that this new Evalution pentaplex can accurately measure the antibody response to TT, DTxd, PT, FHA and Prn. It also has the potential to measure antibody binding and dissociation kinetics.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pauline Lecerf</style></author><author><style face="normal" font="default" size="100%">Roelke De Paepe</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Yasaman Jazaeri</style></author><author><style face="normal" font="default" size="100%">Ann Packeu</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Normand, Anne-Cécile</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Martiny, Delphine</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of a Liquid Media MALDI-TOF MS Protocol for the Identification of Dermatophytes Isolated from  Infections.</style></title><secondary-title><style face="normal" font="default" size="100%">J Fungi (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Nov 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;One of the most common types of tinea is the superficial infection of the hair and scalp area known as tinea capitis. It is responsible for frequent outbreaks in nurseries and schools and represents a global health problem. Correct identification of the infection agent is essential in the determination of the infection source, epidemiological course, and treatment initiation. The conventional identification methods (direct exam, culture, DNA sequencing) are time-consuming, require experienced staff, are time-consuming, and the latter is expensive for routine identifications. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) is gaining new ground for routine identification of filamentous fungi. The main advantages of MALDI-TOF MS are its rapid and accurate identification capability, relatively low cost, and easy integration into the laboratory routine. Its accuracy heavily depends on the quality of the reference spectra database. Identification of clinical isolates with MALDI-TOF MS protocol requires a sub-culturing step to ensure reliable identification. It can take days to weeks before fungal growth appears on solid medium. In this study, a unique MALDI-TOF MS protocol using liquid cultures of dermatophyte species was developed in order to shorten the turnaround time for the culture and identification of clinical isolates. Material and Method A standard MALDI-TOF MS protocol was adapted for liquid instead of solid cultures. Three different databases were tested. Results Using the liquid media MALDI-TOF MS protocol, a global rate of 62% correct identification (RCI) was obtained, compared with 87% for the protocol based on solid cultures. Trichophyton tonsurans was not correctly identified in all isolates using liquid cultures, with 88% of the isolates misidentified as Trichophyton interdigitale. The turnaround time for primary isolates for the solid and liquid protocols were respectively 11.7 and 11.6 days (no significant difference between both methods ( = 0.96)). Conclusions The newly designed liquid MALDI-TOF MS protocol did not lead to a significantly shorter turnaround time for the identification of dermatophytes isolated from tinea capitis infections. The turnaround time for the method with primary isolates was not significantly lower, and the rate of correct identification decreased remarkably, which emphasizes the need for a sub-culturing step. Using different database did not lead to improvement in turnaround time or rate of correct identification. This study highlights the importance of the medium and the reference database when performing MALDI-TOF MS.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elisa Brauns</style></author><author><style face="normal" font="default" size="100%">Abdulkader Azouz</style></author><author><style face="normal" font="default" size="100%">Séverine Thomas</style></author><author><style face="normal" font="default" size="100%">Muriel Nguyen</style></author><author><style face="normal" font="default" size="100%">Véronique Olislagers</style></author><author><style face="normal" font="default" size="100%">Ines Vu Duc</style></author><author><style face="normal" font="default" size="100%">Nicolas Dauby</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author><author><style face="normal" font="default" size="100%">Stanislas Goriely</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">David Grimaldi</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Hanxi Xiao</style></author><author><style face="normal" font="default" size="100%">Jishnu Das</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Carmen Orte Cano</style></author><author><style face="normal" font="default" size="100%">Véronique Del Marmol</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Frédérick Libert</style></author><author><style face="normal" font="default" size="100%">Sven Saussez</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Functional reprogramming of monocytes in patients with acute and convalescent severe COVID-19.</style></title><secondary-title><style face="normal" font="default" size="100%">JCI Insight</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Monocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Apr 05</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Severe COVID-19 disease is associated with dysregulation of the myeloid compartment during acute infection. Survivors frequently experience long-lasting sequelae, but little is known about the eventual persistence of this immune alteration. Herein, we evaluated TLR-induced cytokine responses in a cohort of mild to critical patients during acute or convalescent phases (n = 97). In the acute phase, we observed impaired cytokine production by monocytes in the patients with the most severe COVID-19. This capacity was globally restored in convalescent patients. However, we observed increased responsiveness to TLR1/2 ligation in patients who recovered from severe disease, indicating that these cells display distinct functional properties at the different stages of the disease. In patients with acute severe COVID-19, we identified a specific transcriptomic and epigenomic state in monocytes that can account for their functional refractoriness. The molecular profile of monocytes from recovering patients was distinct and characterized by increased chromatin accessibility at activating protein 1 (AP1) and MAF loci. These results demonstrate that severe COVID-19 infection has a profound impact on the differentiation status and function of circulating monocytes, during both the acute and the convalescent phases, in a completely distinct manner. This could have important implications for our understanding of short- and long-term COVID-19-related morbidity.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marcella Mori</style></author><author><style face="normal" font="default" size="100%">Selimaj Valbona</style></author><author><style face="normal" font="default" size="100%">Alexandra Vodolazkaia</style></author><author><style face="normal" font="default" size="100%">Marina Mukovnikova</style></author><author><style face="normal" font="default" size="100%">Fabrizio De Massis</style></author><author><style face="normal" font="default" size="100%">Giulano Garofolo</style></author><author><style face="normal" font="default" size="100%">Marie-Cécile Nassogne</style></author><author><style face="normal" font="default" size="100%">Dimitri Van der Linden</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Going Chronic: About a complicated case of pediatric brucellosis being the first ‘endemic’ incident of human Brucellosis in Belgium (2021-2022)</style></title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year></dates><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M Bignoumba</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">R Onanga</style></author><author><style face="normal" font="default" size="100%">B S Kumulungui</style></author><author><style face="normal" font="default" size="100%">R F Kassa Kassa</style></author><author><style face="normal" font="default" size="100%">Y Mouanga Ndzime</style></author><author><style face="normal" font="default" size="100%">K Mbombe Moghoa</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Dirk Stubbe</style></author><author><style face="normal" font="default" size="100%">Pierre Becker</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">High diversity of yeast species and strains responsible for vulvovaginal candidiasis in South-East Gabon.</style></title><secondary-title><style face="normal" font="default" size="100%">J Mycol Med</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Nov 25</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">33</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;Candida albicans generally remains the principal pathogenic yeast responsible for vulvovaginal candidiasis (VVC), although with variable prevalence. In this study, we evaluated the evolution of the prevalence of the non-Candida albicans Candida (NCAC) species and investigated the genotypic diversity and the population genetic structure of the circulating C. albicans strains associated with VVC in the vicinity of Franceville (Gabon).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;A total of 110 independent isolates were identified using both MALDI-TOF MS and conventional techniques. The population genetic structure of the C. albicans strains was determined by multiple locus variable-number tandem repeat analysis using 4 microsatellite markers.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The mean and median age of the patients was 31 years. Seven patients had a mixed infection. C. albicans accounted for 62&amp;nbsp;% (n=68) of the total isolates. NCAC were dominated by C. glabrata, followed by P. kudriavzevii, C. parapsilosis, C. tropicalis, M. guilliermondii, and C. nivariensis. The cluster analysis revealed a high diversity, with a total of 50 different genotypes. The most represented genotype was shared by only four strains, while the vast majority (39 strains) had a unique MLVA pattern. Geographic clusters were not detected.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;The study provides information on species distribution and possible changing epidemiology while reporting for the first time C. nivariensis in VVC in Africa. This study is also the first to investigate the genotypic diversity of the circulating C. albicans strains associated with VVC in Central Africa. Such analyses would help understand the molecular epidemiology of C. albicans.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yana Debie</style></author><author><style face="normal" font="default" size="100%">Timon Vandamme</style></author><author><style face="normal" font="default" size="100%">Debbie Le Blon</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Jonas R M Van Audenaerde</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Lieselot Croes</style></author><author><style face="normal" font="default" size="100%">Christof Vulsteke</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Laure-Anne Teuwen</style></author><author><style face="normal" font="default" size="100%">Lise Verbruggen</style></author><author><style face="normal" font="default" size="100%">Greetje Vanhoutte</style></author><author><style face="normal" font="default" size="100%">Elly Marcq</style></author><author><style face="normal" font="default" size="100%">Lisa Verheggen</style></author><author><style face="normal" font="default" size="100%">Bart Peeters</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">Sébastien Anguille</style></author><author><style face="normal" font="default" size="100%">Annelies Janssens</style></author><author><style face="normal" font="default" size="100%">Hans Prenen</style></author><author><style face="normal" font="default" size="100%">Evelien L J Smits</style></author><author><style face="normal" font="default" size="100%">Eva Lion</style></author><author><style face="normal" font="default" size="100%">Peeters, Marc</style></author><author><style face="normal" font="default" size="100%">Peter A van Dam</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Cancer Res</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Nov 07</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;PURPOSE: &lt;/b&gt;Cancer patients display reduced humoral responses after double-dose COVID-19 vaccination while their cellular response is more comparable to that in healthy individuals. Recent studies demonstrated that a third vaccination dose boosts these immune responses, both in healthy people and cancer patients. Due to the availability of many different COVID-19 vaccines, many people have been boosted with a different vaccine from the one used for double-dose vaccination. Data on such alternative vaccination schedules are scarce. This prospective study compares a third dose of BNT162b2 after double-dose BNT162b2 (homologous) versus ChAdOx1 (heterologous) vaccination in cancer patients.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;EXPERIMENTAL DESIGN: &lt;/b&gt;442 subjects (315 patients and 127 healthy) received a third dose of BNT162b2 (230 homologous vs 212 heterologous). Vaccine-induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARSCoV-2 50% neutralization titers (NT50) against Wuhan and BA.1 Omicron strains. Cellular immunity was examined by analyzing CD4+ and CD8+ T cell responses against SARS-CoV-2 specific S1 and S2 peptides.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Local AEs were more common after heterologous boosting. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects (GMT 1755.90 BAU/mL [95% CI 1276.95-2414.48] vs 1495.82 BAU/mL (95% CI 1131.48-1977.46)). However, homologous boosted subjects show significantly higher NT50 values against BA.1 Omicron. Subjects receiving heterologous boosting demonstrated increased spike-specific CD8+ T cells, including higher IFNγ and TNFα levels.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;In cancer patients who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Delphine Kemlin</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Nicolas Gemander</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author><author><style face="normal" font="default" size="100%">Le Moine, Alain</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Anne Lemy</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Hybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Transplant</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Kidney Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Renal Dialysis</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplant Recipients</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">3</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hannah M Garcia Garrido</style></author><author><style face="normal" font="default" size="100%">Bridget van Put</style></author><author><style face="normal" font="default" size="100%">Cornelis A de Pijper</style></author><author><style face="normal" font="default" size="100%">Cornelis Stijnis</style></author><author><style face="normal" font="default" size="100%">Martin P Grobusch</style></author><author><style face="normal" font="default" size="100%">Abraham Goorhuis</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sanne Terryn</style></author><author><style face="normal" font="default" size="100%">Steven Van Gucht</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Geert R D'Haens</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Phyllis I Spuls</style></author><author><style face="normal" font="default" size="100%">Marleen G Van de Sande</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunogenicity and one-year boostability of a 3-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-Centre clinical trial.</style></title><secondary-title><style face="normal" font="default" size="100%">J Travel Med</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Dec 08</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;For immunocompromised patients (ICPs), administration of rabies immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the one-year boostability of a 3-dose rabies pre-exposure prophylaxis (PrEP) schedule in individuals using immunosuppressive monotherapy.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;In this prospective study, individuals on immunosuppressive monotherapy with a conventional immunomodulator (cIM) or a TNF-alpha inhibitor (TNFi) for a chronic inflammatory disease received a 3-dose intramuscular PrEP schedule (days 0,7,21-28) with 1&amp;nbsp;mL Rabipur®, followed by a 2-dose simulated post-exposure prophylaxis (PEP) schedule (days 0,3) after 12&amp;nbsp;months. Rabies neutralizing antibodies were assessed at baseline, on Day 21-28 (before 3rd PrEP dose), Day 60, Month 12 and Month 12 + 7&amp;nbsp;days. The primary outcome was one-year boostability, defined as the proportion of patients with a neutralizing antibody titre of ≥ 0.5&amp;nbsp;IU/mL at Month 12 + 7&amp;nbsp;days. Secondary outcomes were geometric mean titres and factors associated with the primary endpoint.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We included 56 individuals, of whom 52 completed the study. The one-year boostability was 90% (47/52) with a GMT of 6.16 (95% CI 3.83-9.91). All participants seroconverted at some point in the study. Early response to PrEP (at day 21-28) was significantly associated with 100% boostability (Odds ratio 51; 95% confidence interval [5.0-6956], p &amp;lt; 0.01). The vaccination schedule was safe and well tolerated. No vaccine-related serious adverse events occurred.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;In patients using immunosuppressive monotherapy, a 3-dose rabies PrEP schedule followed by a 2-dose PEP schedule is immunogenic, with all patients seroconverting at some point in the study. Although boostability 7&amp;nbsp;days after PEP was not 100%, nobody would wrongly be denied RIG when only administered to those who responded early to PrEP, while reducing administration of RIG by 73%.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frédéric Baron</style></author><author><style face="normal" font="default" size="100%">Lorenzo Canti</style></author><author><style face="normal" font="default" size="100%">Yves Beguin</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Delphine Kemlin</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Margaux Gerbaux</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author><author><style face="normal" font="default" size="100%">Stéphanie Humblet-Baron</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Immunol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">2019-nCoV Vaccine mRNA-1273</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunocompromised Host</style></keyword><keyword><style  face="normal" font="default" size="100%">mRNA Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccines, Synthetic</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;It is critical to protect immunocompromised patients against COVID-19 with effective SARS-CoV-2 vaccination as they have an increased risk of developing severe disease. This is challenging, however, since effective mRNA vaccination requires the successful cooperation of several components of the innate and adaptive immune systems, both of which can be severely affected/deficient in immunocompromised people. In this article, we first review current knowledge on the immunobiology of SARS-COV-2 mRNA vaccination in animal models and in healthy humans. Next, we summarize data from early trials of SARS-COV-2 mRNA vaccination in patients with secondary or primary immunodeficiency. These early clinical trials identified common predictors of lower response to the vaccine such as anti-CD19, anti-CD20 or anti-CD38 therapies, low (naive) CD4 T-cell counts, genetic or therapeutic Bruton tyrosine kinase deficiency, treatment with antimetabolites, CTLA4 agonists or JAK inhibitors, and vaccination with BNT162b2 versus mRNA1273 vaccine. Finally, we review the first data on third dose mRNA vaccine administration in immunocompromised patients and discuss recent strategies of temporarily holding/pausing immunosuppressive medication during vaccination.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arnaud Jabet</style></author><author><style face="normal" font="default" size="100%">Normand, Anne-Cécile</style></author><author><style face="normal" font="default" size="100%">Cécile Nabet</style></author><author><style face="normal" font="default" size="100%">Piarroux, Renaud</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Alicia Moreno-Sabater</style></author></secondary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Jacques Guillot</style></author><author><style face="normal" font="default" size="100%">Veronica Risco-Castillo</style></author><author><style face="normal" font="default" size="100%">Sophie Brun</style></author><author><style face="normal" font="default" size="100%">Magalie Demar</style></author><author><style face="normal" font="default" size="100%">Romain Blaizot</style></author><author><style face="normal" font="default" size="100%">Ann Packeu</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Investigations upon the Improvement of Dermatophyte Identification Using an Online Mass Spectrometry Application.</style></title><secondary-title><style face="normal" font="default" size="100%">J Fungi (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jan 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Online MALDI-TOF mass spectrometry applications, such as MSI-2, have been shown to help identify dermatophytes, but recurrent errors are still observed between phylogenetically close species. The objective of this study was to assess different approaches to reduce the occurrence of such errors by adding new reference spectra to the MSI-2 application. Nine libraries were set up, comprising an increasing number of spectra obtained from reference strains that were submitted to various culture durations on two distinct culture media: Sabouraud gentamicin chloramphenicol medium and IDFP Conidia medium. The final library included spectra from 111 strains of 20 species obtained from cultures on both media collected every three days after the appearance of the colony. The performance of each library was then analyzed using a cross-validation approach. The spectra acquisitions were carried out using a Microflex Bruker spectrometer. Diversifying the references and adding spectra from various culture media and culture durations improved identification performance. The percentage of correct identification at the species level rose from 63.4 to 91.7% when combining all approaches. Nevertheless, residual confusion between close species, such as , and , remained. To distinguish between these species, mass spectrometry identification should take into account basic morphological and/or clinico-epidemiological features.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Normand, Anne-Cécile</style></author><author><style face="normal" font="default" size="100%">Arnaud Jabet</style></author><author><style face="normal" font="default" size="100%">Marion Blaize</style></author><author><style face="normal" font="default" size="100%">Piarroux, Renaud</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Alicia Moreno-Sabater</style></author></secondary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Samia Hamane</style></author><author><style face="normal" font="default" size="100%">Geneviève Cremer</style></author><author><style face="normal" font="default" size="100%">Françoise Foulet</style></author><author><style face="normal" font="default" size="100%">Sarah Dellière</style></author><author><style face="normal" font="default" size="100%">Christine Bonnal</style></author><author><style face="normal" font="default" size="100%">Sébastien Imbert</style></author><author><style face="normal" font="default" size="100%">Sophie Brun</style></author><author><style face="normal" font="default" size="100%">Ann Packeu</style></author><author><style face="normal" font="default" size="100%">Stéphane Bretagne</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">MALDI-TOF Mass Spectrometry Online Identification of  Using the MSI-2 Application.</style></title><secondary-title><style face="normal" font="default" size="100%">J Fungi (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Oct 19</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;is an emerging pathogen which recently spread from India to Europe and that is more prone than other species of the complex to show resistance to terbinafine, resulting in the necessity of rapid identification. Here, we improved the online MSI-2 MALDI-TOF identification tool in order to identify . By multiplying the culture conditions (2 culture media and 6 stages of growth) prior to protein extractions for both test isolates and reference strains, we added 142 references corresponding to 12 strains inside the complex in the online MSI-2 database, of which 3 are strains. The resulting database was tested with 1566 spectra of 67 isolates from the complex, including 16 isolates. Using the newly improved MSI-2 database, we increased the identification rate of from 5% to 96%, with a sensitivity of 99.6%. We also identified specific peaks (6834/6845 daltons and 10,634/10,680 daltons) allowing for the distinction of from the other species of the complex. Our improved version of the MSI-2 application allows for the identification of . This will improve the epidemiological knowledge of the spread of this species throughout the world and will help to improve patient care.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elena Menchi</style></author><author><style face="normal" font="default" size="100%">Karim Amighi</style></author><author><style face="normal" font="default" size="100%">Nathalie Wauthoz</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">El Khattabi, Charaf</style></author><author><style face="normal" font="default" size="100%">Stéphanie Pochet</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Optimization of Long-Acting Bronchodilator Dose Ratios Using Isolated Guinea Pig Tracheal Rings for Synergistic Combination Therapy in Asthma and COPD.</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmaceuticals (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Aug 03</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The co-administration of a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), has been shown to be beneficial in the management of non-communicable chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The resulting relaxation of the airways can be synergistically enhanced, reducing symptoms and optimizing lung function. This provides an insight into more effective treatments. In this study, the LABAs formoterol fumarate dihydrate (FOR) and indacaterol maleate (IND) were each associated with tiotropium bromide monohydrate (TIO) to assess their synergistic potential. This was done using an appropriate ex vivo model of isolated perfused guinea pig tracheal rings, and pharmacological models of drug interaction. Among the dose ratios studied for both types of combination, a higher synergistic potential was highlighted for FOR/TIO 2:1 (). This was done through three steps by using multiple additions of drugs to the organ baths based on a non-constant dose ratio and then on a constant dose ratio, and by a single addition to the organ baths of specific amounts of drugs. In this way, the synergistic improvement of the relaxant effect on the airways was confirmed, providing a basis for improving therapeutic approaches in asthma and COPD. The synergy found at this dose ratio should now be confirmed on a preclinical model of asthma and COPD by assessing lung function.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angelina Konnova</style></author><author><style face="normal" font="default" size="100%">Fien H R De Winter</style></author><author><style face="normal" font="default" size="100%">Gupta, Akshita</style></author><author><style face="normal" font="default" size="100%">An Hotterbeekx</style></author><author><style face="normal" font="default" size="100%">Matilda Berkell</style></author><author><style face="normal" font="default" size="100%">Samir Kumar-Singh</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Goossens, Herman</style></author><author><style face="normal" font="default" size="100%">Surbhi Malhotra-Kumar</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Lise Verbruggen</style></author><author><style face="normal" font="default" size="100%">Greetje Vanhoutte</style></author><author><style face="normal" font="default" size="100%">Silke Raats</style></author><author><style face="normal" font="default" size="100%">Isolde Van der Massen</style></author><author><style face="normal" font="default" size="100%">Sven De Keersmaecker</style></author><author><style face="normal" font="default" size="100%">Yana Debie</style></author><author><style face="normal" font="default" size="100%">Zwi Berneman</style></author><author><style face="normal" font="default" size="100%">Timon Vandamme</style></author><author><style face="normal" font="default" size="100%">Peeters, Marc</style></author><author><style face="normal" font="default" size="100%">Peter van Dam</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Laure-Anne Teuwen</style></author><author><style face="normal" font="default" size="100%">Bart Peeters</style></author><author><style face="normal" font="default" size="100%">Manon Huizing</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Kristof Y Neven</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">Geert A Martens</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">Ella Roelant</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Sébastien Anguille</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author><author><style face="normal" font="default" size="100%">Evelina Tacconelli</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Immunol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Intercellular Signaling Peptides and Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Placenta Growth Factor</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccines</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;We employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune- and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;C-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory cytokine), IL-18 (interferon-gamma inducing factor), and placental growth factor (an angiogenic cytokine) correctly classified patients with a diminished vaccine response assessed at day 49 with &amp;gt;80% accuracy. Amongst these, CRP showed the highest predictive value for poor response to vaccine administration. Importantly, this unique signature of vaccine response was present at different studied timepoints both before and after vaccination and was not majorly affected by different anti-cancer treatments.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;We propose a blood-based signature of cytokines and growth factors that can be employed in identifying cancer patients at persistent high risk of COVID-19 despite vaccination with BNT162b2. Our data also suggest that such a signature may reflect the inherent immunological constitution of some cancer patients who are refractive to immunotherapy.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niels Adriaenssens</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Beatrice Scholtes</style></author><author><style face="normal" font="default" size="100%">Laëtitia Buret</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Bruyndonckx, Robin</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Jan Y Verbakel</style></author><author><style face="normal" font="default" size="100%">An De Sutter</style></author><author><style face="normal" font="default" size="100%">Stefan Heytens</style></author><author><style face="normal" font="default" size="100%">Ann Van Den Bruel</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Van Damme, Pierre</style></author><author><style face="normal" font="default" size="100%">Goossens, Herman</style></author><author><style face="normal" font="default" size="100%">Els Duysburgh</style></author><author><style face="normal" font="default" size="100%">Coenen, Samuel</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">incidence</style></keyword><keyword><style  face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Seroepidemiologic Studies</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jan 31</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;INTRODUCTION: &lt;/b&gt;National SARS-CoV-2 seroprevalence data provide essential information about population exposure to the virus and help predict the future course of the epidemic. Early cohort studies have suggested declines in levels of antibodies in individuals associated with, for example, illness severity, age and comorbidities. This protocol focuses on the seroprevalence among primary healthcare providers (PHCPs) in Belgium. PHCPs manage the vast majority of (COVID-19) patients and therefore play an essential role in the efficient organisation of healthcare. Currently, evidence is lacking on (1) how many PHCPs get infected with SARS-CoV-2 in Belgium, (2) the rate at which this happens, (3) their clinical spectrum, (4) their risk factors, (5) the effectiveness of the measures to prevent infection and (6) the accuracy of the serology-based point-of-care test (POCT) in a primary care setting.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS AND ANALYSIS: &lt;/b&gt;This study will be set up as a prospective cohort study. General practitioners (GPs) and other PHCPs (working in a GP practice) will be recruited via professional networks and professional media outlets to register online to participate. Registered GPs and other PHCPs will be asked at each testing point (n=9) to perform a capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2 and complete an online questionnaire. The primary outcomes are the prevalence and incidence of antibodies against SARS-CoV-2 in PHCPs during a 12-month follow-up period. Secondary outcomes include the longevity of antibodies against SARS-CoV-2.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;ETHICS AND DISSEMINATION: &lt;/b&gt;Ethical approval has been granted by the ethics committee of the University Hospital of Antwerp/University of Antwerp (Belgian registration number: 3002020000237). Alongside journal publications, dissemination activities include the publication of monthly reports to be shared with the participants and the general population through the publicly available website of the Belgian health authorities (Sciensano).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;TRIAL REGISTRATION NUMBER: &lt;/b&gt;NCT04779424.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niels Adriaenssens</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Beatrice Scholtes</style></author><author><style face="normal" font="default" size="100%">Pauline Van Ngoc</style></author><author><style face="normal" font="default" size="100%">Laëtitia Buret</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Bruyndonckx, Robin</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Jan Yvan Jos Verbakel</style></author><author><style face="normal" font="default" size="100%">An De Sutter</style></author><author><style face="normal" font="default" size="100%">Stefan Heytens</style></author><author><style face="normal" font="default" size="100%">Ann Van Den Bruel</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Van Damme, Pierre</style></author><author><style face="normal" font="default" size="100%">Goossens, Herman</style></author><author><style face="normal" font="default" size="100%">Els Duysburgh</style></author><author><style face="normal" font="default" size="100%">Coenen, Samuel</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin M</style></keyword><keyword><style  face="normal" font="default" size="100%">incidence</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">prevalence</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Seroepidemiologic Studies</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Sep 19</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;To estimate the prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;DESIGN: &lt;/b&gt;Prospective cohort study with 12 months of follow-up.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;SETTING: &lt;/b&gt;Primary care in Belgium.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;PARTICIPANTS: &lt;/b&gt;Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3648 eligible PHCPs from 2001 GP practices registered for this study (3044 and 604 to start in December 2020 and January 2021, respectively). 3390 PHCPs (92,9%) participated in their first testing time point (2820 and 565, respectively) and 2557 PHCPs (70,1%) in the last testing time point (December 2021).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;INTERVENTIONS: &lt;/b&gt;Participants were asked to perform a rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2 and to complete an online questionnaire at each of maximum eight testing time points.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;PRIMARY AND SECONDARY OUTCOME MEASURES: &lt;/b&gt;The prevalence, incidence and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI 13.5% to 16.6%), increased to 84.2% (95% CI 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) COVID-19 wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;TRIAL REGISTRATION NUMBER: &lt;/b&gt;NCT04779424.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">C. Bian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Y. Kusuya</style></author><author><style face="normal" font="default" size="100%">T. Yaguchi</style></author><author><style face="normal" font="default" size="100%">S. Ban</style></author><author><style face="normal" font="default" size="100%">V. Hubka</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">F. Sklenar</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Elizabet D'hooge</style></author><author><style face="normal" font="default" size="100%">C.M. Visagie</style></author><author><style face="normal" font="default" size="100%">J. Houbraken</style></author><author><style face="normal" font="default" size="100%">H. Takahashi</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reducing the number of accepted species in Aspergillus series Nigri</style></title><secondary-title><style face="normal" font="default" size="100%">Studies in Mycology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ASPERGILLUS LUCHUENSIS</style></keyword><keyword><style  face="normal" font="default" size="100%">ASPERGILLUS NIGER</style></keyword><keyword><style  face="normal" font="default" size="100%">ASPERGILLUS TUBINGENSIS</style></keyword><keyword><style  face="normal" font="default" size="100%">CLINICAL FUNGI</style></keyword><keyword><style  face="normal" font="default" size="100%">INDOOR FUNGI</style></keyword><keyword><style  face="normal" font="default" size="100%">INFRASPECIFIC VARIABILITY</style></keyword><keyword><style  face="normal" font="default" size="100%">MULTIGENE PHYLOGENY</style></keyword><keyword><style  face="normal" font="default" size="100%">MULTISPECIES COALESCENCE MODEL</style></keyword><keyword><style  face="normal" font="default" size="100%">Ochratoxin A</style></keyword><keyword><style  face="normal" font="default" size="100%">SPECIES DELIMITATION</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year></dates><number><style face="normal" font="default" size="100%">132(38)</style></number><volume><style face="normal" font="default" size="100%">102</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><section><style face="normal" font="default" size="100%">95</style></section></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maud Deny</style></author><author><style face="normal" font="default" size="100%">Luis Alexis Arroba Nuñez</style></author><author><style face="normal" font="default" size="100%">Georges Casimir</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Mustapha Chamekh</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Sex difference in innate inflammatory response and macrophage polarization in Streptococcus agalactiae-induced pneumonia and potential role of microRNA-223-3p.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antagomirs</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">MicroRNAs</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">Sex Characteristics</style></keyword><keyword><style  face="normal" font="default" size="100%">Streptococcus agalactiae</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Oct 12</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;While number of studies have shown that biological sex is a risk factor in the incidence and severity of infection-induced inflammatory diseases, the underlying mechanisms are still poorly understood. In this study, we compared the innate inflammatory response in male and female mice with group B streptococcal (GBS)-induced pneumoniae. Although male and female mice displayed similar bacterial burdens, males exhibited more innate inflammatory cytokines and chemokines and a higher proportion of infiltrating monocytes/macrophages. The analysis of the distribution of macrophage subtypes M1 (pro-inflammatory) versus M2 (anti-inflammatory) yielded a higher M1/M2 ratio in infected males compared with females. Given the importance of the chromosome X-linked microRNA-223-3p (miR-223-3p) in modulating the inflammatory process and macrophage polarization, we investigated its potential contribution in sex bias of GBS-induced innate inflammatory response. Knock-down of miR-223-3p with specific antagomiR resulted in increased inflammatory response and higher M1/M2 ratio following GBS infection. Notably, compared to male mice, we detected higher amount of miR-223-3p in macrophages from females that correlated negatively with M1 phenotype. These results suggest that differential expression of miR-233-3p may impact macrophage polarization, thereby contributing to fine-tune sex differences in inflammatory response.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">Heyndrickx, Leo</style></author><author><style face="normal" font="default" size="100%">Johan Michiels</style></author><author><style face="normal" font="default" size="100%">Katleen Vereecken</style></author><author><style face="normal" font="default" size="100%">Sandra Coppens</style></author><author><style face="normal" font="default" size="100%">Betty Willems</style></author><author><style face="normal" font="default" size="100%">Koen Bartholomeeusen</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Kurt Van Lent</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Geert A Martens</style></author><author><style face="normal" font="default" size="100%">Van Esbroeck, Marjan</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant.</style></title><secondary-title><style face="normal" font="default" size="100%">NPJ Vaccines</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Mar 08</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in unimmunized infected (group 1), immunised and boosted (group 2) and infected immunised and boosted (group 3) adult individuals. Our observations support the rapid administration of a booster vaccine dose to prevent infection and disease caused by Omicron.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bryan Gosselin</style></author><author><style face="normal" font="default" size="100%">Maurice Retout</style></author><author><style face="normal" font="default" size="100%">Raphaël Dutour</style></author><author><style face="normal" font="default" size="100%">Lefèvre, Philippe</style></author><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author><author><style face="normal" font="default" size="100%">Gilles Bruylants</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ludovic Troian-Gautier</style></author><author><style face="normal" font="default" size="100%">Robin Bevernaegie</style></author><author><style face="normal" font="default" size="100%">Ivan Jabin</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Sophie Herens</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ultrastable Silver Nanoparticles for Rapid Serology Detection of Anti-SARS-CoV-2 Immunoglobulins G.</style></title><secondary-title><style face="normal" font="default" size="100%">Anal Chem</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Calixarenes</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Gold</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoassay</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Metal Nanoparticles</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Silver</style></keyword><keyword><style  face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 May 24</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">94</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Dipstick assays using silver nanoparticles (AgNPs) stabilized by a thin calix[4]arene-based coating were developed and used for the detection of Anti-SARS-CoV-2 IgG in clinical samples. The calixarene-based coating enabled the covalent bioconjugation of the SARS-CoV-2 Spike Protein via the classical EDC/sulfo-NHS procedure. It further conferred remarkable stability to the resulting bioconjugated AgNPs, as no degradation was observed over several months. In comparison with lateral-flow immunoassays (LFIAs) based on classical gold nanoparticles, our AgNP-based system constitutes a clear step forward, as the limit of detection for Anti-SARS-CoV-2 IgG was reduced by 1 order of magnitude and similar signals were observed with 10 times fewer particles. In real clinical samples, the AgNP-based dipstick assays showed impressive results: 100% specificity was observed for negative samples, while a sensitivity of 73% was determined for positive samples. These values match the typical sensitivities obtained for reported LFIAs based on gold nanoparticles. These results (i) represent one of the first examples of the use of AgNP-based dipstick assays in the case of real clinical samples, (ii) demonstrate that ultrastable calixarene-coated AgNPs could advantageously replace AuNPs in LFIAs, and thus (iii) open new perspectives in the field of rapid diagnostic tests.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">20</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Laura Van Poelvoorde</style></author><author><style face="normal" font="default" size="100%">Kevin Vanneste</style></author><author><style face="normal" font="default" size="100%">Sigrid C.J. De Keersmaecker</style></author><author><style face="normal" font="default" size="100%">Nancy Roosens</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Isabelle Thomas</style></author><author><style face="normal" font="default" size="100%">Steven Van Gucht</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Saelens, Xavier</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Nina Van Goethem</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Whole-Genome Sequence Approach and Phylogenomic Stratification Improve the Association Analysis of Mutations With Patient Data in Influenza Surveillance.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Microbiol</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Each year, seasonal influenza results in high mortality and morbidity. The current classification of circulating influenza viruses is mainly focused on the hemagglutinin gene. Whole-genome sequencing (WGS) enables tracking mutations across all influenza segments allowing a better understanding of the epidemiological effects of intra- and inter-seasonal evolutionary dynamics, and exploring potential associations between mutations across the viral genome and patient's clinical data. In this study, mutations were identified in 253 Influenza A (H3N2) clinical isolates from the 2016-2017 influenza season in Belgium. As a proof of concept, available patient data were integrated with this genomic data, resulting in statistically significant associations that could be relevant to improve the vaccine and clinical management of infected patients. Several mutations were significantly associated with the sampling period. A new approach was proposed for exploring mutational effects in highly diverse Influenza A (H3N2) strains through considering the viral genetic background by using phylogenetic classification to stratify the samples. This resulted in several mutations that were significantly associated with patients suffering from renal insufficiency. This study demonstrates the usefulness of using WGS data for tracking mutations across the complete genome and linking these to patient data, and illustrates the importance of accounting for the viral genetic background in association studies. A limitation of this association study, especially when analyzing stratified groups, relates to the number of samples, especially in the context of national surveillance of small countries. Therefore, we investigated if international databases like GISAID may help to verify whether observed associations in the Belgium A (H3N2) samples, could be extrapolated to a global level. This work highlights the need to construct international databases with both information of viral genome sequences and patient data.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guy Berbers</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Pieter Van Gageldonk</style></author><author><style face="normal" font="default" size="100%">Jan van de Kassteele</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Ursula Wiedermann</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Tine Dalby</style></author><author><style face="normal" font="default" size="100%">Julie Toubiana</style></author><author><style face="normal" font="default" size="100%">Tsiodras, Sotirios</style></author><author><style face="normal" font="default" size="100%">Ildikó Paluska Ferencz</style></author><author><style face="normal" font="default" size="100%">Kathryn Mullan</style></author><author><style face="normal" font="default" size="100%">Algirdas Griskevicius</style></author><author><style face="normal" font="default" size="100%">Tatjana Kolupajeva</style></author><author><style face="normal" font="default" size="100%">Vestrheim, Didrik Frimann</style></author><author><style face="normal" font="default" size="100%">Paula Palminha</style></author><author><style face="normal" font="default" size="100%">Odette Popovici</style></author><author><style face="normal" font="default" size="100%">Lena Wehlin</style></author><author><style face="normal" font="default" size="100%">Tamara Kastrin</style></author><author><style face="normal" font="default" size="100%">Lucia Maďarová</style></author><author><style face="normal" font="default" size="100%">Helen Campbell</style></author><author><style face="normal" font="default" size="100%">Csaba Ködmön</style></author><author><style face="normal" font="default" size="100%">Sabrina Bacci</style></author><author><style face="normal" font="default" size="100%">Alex-Mikael Barkoff</style></author><author><style face="normal" font="default" size="100%">He, Qiushui</style></author></subsidiary-authors><translated-authors><author><style face="normal" font="default" size="100%">Serosurveillance Study Team</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Commun</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Bordetella pertussis</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria-Tetanus-Pertussis Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Seroepidemiologic Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Tetanus</style></keyword><keyword><style  face="normal" font="default" size="100%">Whooping Cough</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 May 17</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Reported incidence of pertussis in the European Union (EU) and the European Economic Area (EEA) varies and may not reflect the real situation, while vaccine-induced protection against diphtheria and tetanus seems sufficient. We aimed to determine the seroprevalence of DTP antibodies in EU/EEA countries within the age groups of 40-49 and 50-59 years. Eighteen countries collected around 500 samples between 2015 and 2018 (N = 10,302) which were analysed for IgG-DTP specific antibodies. The proportion of sera with pertussis toxin antibody levels ≥100 IU/mL, indicative of recent exposure to pertussis was comparable for 13/18 countries, ranging between 2.7-5.8%. For diphtheria the proportion of sera lacking the protective level (&amp;lt;0.1 IU/mL) varied between 22.8-82.0%. For tetanus the protection was sufficient. Here, we report that the seroprevalence of pertussis in these age groups indicates circulation of B. pertussis across EU/EEA while the lack of vaccine-induced seroprotection against diphtheria is of concern and deserves further attention.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Normand, Anne-Cécile</style></author><author><style face="normal" font="default" size="100%">Sébastien Imbert</style></author><author><style face="normal" font="default" size="100%">Piarroux, Renaud</style></author><author><style face="normal" font="default" size="100%">Arnaud Fekkar</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sophie Brun</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Abdullah M S Al-Hatmi,</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Erja Chryssanthou</style></author><author><style face="normal" font="default" size="100%">Sophie Cassaing</style></author><author><style face="normal" font="default" size="100%">Christine Schuttler</style></author><author><style face="normal" font="default" size="100%">Lilia Hasseine</style></author><author><style face="normal" font="default" size="100%">Caroline Mahinc</style></author><author><style face="normal" font="default" size="100%">Damien Costa</style></author><author><style face="normal" font="default" size="100%">Christine Bonnal</style></author><author><style face="normal" font="default" size="100%">Ranque, Stéphane</style></author><author><style face="normal" font="default" size="100%">Marc Sautour</style></author><author><style face="normal" font="default" size="100%">Elisa Rubio</style></author><author><style face="normal" font="default" size="100%">Delhaes, Laurence</style></author><author><style face="normal" font="default" size="100%">Arnaud Riat</style></author><author><style face="normal" font="default" size="100%">Boualem Sendid</style></author><author><style face="normal" font="default" size="100%">Lise Kristensen</style></author><author><style face="normal" font="default" size="100%">Marcel Brandenberger</style></author><author><style face="normal" font="default" size="100%">Juliette Guitard</style></author><author><style face="normal" font="default" size="100%">Ann Packeu</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Origin and Species Distribution of  spp. Isolates Identified by Molecular Sequencing and Mass Spectrometry: A European Multicenter Hospital Prospective Study.</style></title><secondary-title><style face="normal" font="default" size="100%">J Fungi (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Mar 25</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;spp. are widespread environmental fungi as well as pathogens that can affect plants, animals and humans. Yet the epidemiology of human fusariosis is still cloudy due to the rapidly evolving taxonomy. The Mass Spectrometry Identification database (MSI) has been developed since 2017 in order to allow a fast, accurate and free-access identification of fungi by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Taking advantage of the MSI database user network, we aim to study the species distribution of spp. isolates in an international multicenter prospective study. This study also allowed the assessment of the abilities of miscellaneous techniques to identify isolates at the species level. The identification was performed by PCR-sequencing and phylogenic-tree approach. Both methods are used as gold standard for the evaluation of mass spectrometry. Identification at the species complex was satisfactory for all the tested methods. However, identification at the species level was more challenging and only 32% of the isolates were correctly identified with the National Center for Biotechnology Information (NCBI) DNA database, 20% with the Bruker MS database and 43% with the two MSI databases. Improvement of the mass spectrometry database is still needed to enable precise identification at the species level of any isolates encountered either in human pathology or in the environment.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joachim Mariën</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ann Ceulemans</style></author><author><style face="normal" font="default" size="100%">Johan Michiels</style></author><author><style face="normal" font="default" size="100%">Heyndrickx, Leo</style></author><author><style face="normal" font="default" size="100%">Karen Kerkhof</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Nikki Foque</style></author><author><style face="normal" font="default" size="100%">Van Esbroeck, Marjan</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Marc-Alain Widdowson</style></author><author><style face="normal" font="default" size="100%">Laure Mortgat</style></author><author><style face="normal" font="default" size="100%">Els Duysburgh</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Hilde Jansens</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.</style></title><secondary-title><style face="normal" font="default" size="100%">J Virol Methods</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoassay</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin M</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutralization Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Nucleocapsid Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Roc Curve</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Spike Glycoprotein, Coronavirus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">288</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and affordable. Many assays are either labour-intensive and require specialised facilities (e.g. virus neutralization assays), or are expensive with suboptimal specificity (e.g. commercial ELISAs and RDTs). Bead-based assays offer a cost-effective alternative and allow for multiplexing to test for antibodies against multiple antigens and against other pathogens. Here, we compare the performance of spike (S) and nucleocapsid (NP) antigens for the detection of SARS-CoV-2 specific IgG, IgM and IgA antibodies in a panel of sera that includes recent (up to six weeks after symptom onset, severe n = 44; and mild cases n = 52) and old infections (five months after symptom onset, mild n = 104), using a Luminex-bead based assay and comparison to a virus neutralization test. While we show that neutralizing antibody levels are significantly lower in mild than in severe cases, we demonstrate that a combination of the recombinant nucleocapsid protein (NP) and receptor-binding domain (RBD) results in highly specific (99 %) IgG antibody detection five months after infection in 96 % of cases. Although most severe Covid-19 cases developed a clear IgM and IgA response, titers fell below the detection threshold in more than 20 % of mild cases in our bead-based assay. In conclusion, our data supports the use of RBD and NP for the development of SARS-CoV-2 serological IgG bead-based assays.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Normand, Anne-Cécile</style></author><author><style face="normal" font="default" size="100%">Marion Blaize</style></author><author><style face="normal" font="default" size="100%">Sébastien Imbert</style></author><author><style face="normal" font="default" size="100%">Arnaud Fekkar</style></author><author><style face="normal" font="default" size="100%">Piarroux, Renaud</style></author></authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Ann Packeu</style></author><author><style face="normal" font="default" size="100%">Pierre Becker</style></author><author><style face="normal" font="default" size="100%">Dirk Stubbe</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of Molds with Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry: Performance of the Newly Developed MSI-2 Application in Comparison with the Bruker Filamentous Fungi Database and MSI-1.</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Microbiol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aspergillus</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Fungi</style></keyword><keyword><style  face="normal" font="default" size="100%">Fusarium</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Sep 20</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">59</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) represents a promising tool for the rapid and efficient identification of molds, but improvements are still necessary to achieve satisfactory results when identifying cryptic species. Here, we aimed to validate a new web application, MSI-2, which replaces MSI-1, an application that was built and deployed online in 2017. For the evaluation, we gathered 633 challenging isolates obtained from daily hospital practice that were first identified with DNA-based methods, and we submitted their corresponding mass spectra to three identification programs (Bruker, MSI-1, and MSI-2). The MSI-2 application had a better identification performance at the species level than MSI-1 and Bruker, reaching 83.25% correct identifications, compared with 63.19% (MSI-1), 38.07% (Bruker with a 1.7 threshold), and 21.8% (Bruker with a 2.0 threshold). The MSI-2 application performed especially well for Aspergillus and Fusarium species, including for many cryptic species, reaching 90% correct identifications for Aspergillus species and 78% for Fusarium species compared to 69% and 43% with MSI-1. Such an improvement may have a positive impact on patient management by facilitating the identification of cryptic species potentially associated with a specific antifungal resistance profile.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdillah, Abdourahim</style></author><author><style face="normal" font="default" size="100%">Ranque, Stéphane</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Saber Khelaifia</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Ann Packeu</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Intra- and inter-laboratory comparison of mDixon and FastFung broths for Malassezia antifungal susceptibility testing.</style></title><secondary-title><style face="normal" font="default" size="100%">Mycoses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antifungal Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Dermatomycoses</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Laboratories</style></keyword><keyword><style  face="normal" font="default" size="100%">Malassezia</style></keyword><keyword><style  face="normal" font="default" size="100%">Microbial Sensitivity Tests</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">64</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Malassezia spp. antifungal susceptibility testing (AFST) capacities are limited by the lack of efficient and standardised AFST procedure, mainly because of the fastidious cultivation of these yeast.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;This study aimed to compare the FastFung broth (FFB) to modified Dixon broth (mDIXB) for the in vitro AFST of Malassezia spp. Fluconazole, ketoconazole, voriconazole and terbinafine MICs against a 19 Malassezia strains, including 6&amp;nbsp;M furfur, 4&amp;nbsp;M pachydermatis, 5&amp;nbsp;M sympodialis and 4&amp;nbsp;M slooffiae.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;The essential agreement (EA) between the two assays, and the intra- and inter-laboratory agreement of each assay were assessed.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The MIC data obtained in our study were comparable to those reported in the literature. FFB showed to enhance Malassezia growth and displayed 100% (±2-fold dilution) EAs demonstrating similar performances to mDIXB. In addition, the MIC data obtained by using the FFB were reproducible between laboratories with EAs ranging from 94.7% to 100%.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Therefore, FFB is a suitable alternative to mDXB for Malassezia spp. AFST.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mariateresa Coppola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fabienne Jurion</style></author><author><style face="normal" font="default" size="100%">Tima, Hermann Giresse</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Susan J F Van den Eeden</style></author><author><style face="normal" font="default" size="100%">Franken, Kees L M C</style></author><author><style face="normal" font="default" size="100%">Annemieke Geluk</style></author><author><style face="normal" font="default" size="100%">Ottenhoff, Tom H M</style></author></tertiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination.</style></title><secondary-title><style face="normal" font="default" size="100%">NPJ Vaccines</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jun 03</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Novel tuberculosis (TB)-vaccines preferably should (i) boost host immune responses induced by previous BCG vaccination and (ii) be directed against Mycobacterium tuberculosis (Mtb) proteins expressed throughout the Mtb infection-cycle. Human Mtb antigen-discovery screens identified antigens encoded by Mtb-genes highly expressed during in vivo murine infection (IVE-TB antigens). To translate these findings towards animal models, we determined which IVE-TB-antigens are recognised by T-cells following Mtb challenge or BCG vaccination in three different mouse strains. Eleven Mtb-antigens were recognised across TB-resistant and susceptible mice. Confirming previous human data, several Mtb-antigens induced cytokines other than IFN-γ. Pulmonary cells from susceptible C3HeB/FeJ mice produced less TNF-α, agreeing with the TB-susceptibility phenotype. In addition, responses to several antigens were induced by BCG in C3HeB/FeJ mice, offering potential for boosting. Thus, recognition of promising Mtb-antigens identified in humans validates across multiple mouse TB-infection models with widely differing TB-susceptibilities. This offers translational tools to evaluate IVE-TB-antigens as diagnostic and vaccine antigens.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ku, Min Wen</style></author><author><style face="normal" font="default" size="100%">Pierre Authié</style></author><author><style face="normal" font="default" size="100%">Fabien Nevo</style></author><author><style face="normal" font="default" size="100%">Maryline Bourgine</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Philippe Souque</style></author></secondary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Pierre Charneau</style></author><author><style face="normal" font="default" size="100%">Majlessi, Laleh</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Lentiviral vector induces high-quality memory T cells via dendritic cells transduction.</style></title><secondary-title><style face="normal" font="default" size="100%">Commun Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">beta 2-Microglobulin</style></keyword><keyword><style  face="normal" font="default" size="100%">CD8-Positive T-Lymphocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">genetic engineering</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Vectors</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Cellular</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunologic Memory</style></keyword><keyword><style  face="normal" font="default" size="100%">Lentivirus</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">Promoter Regions, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Transduction, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Transgenes</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jun 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">4</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We report a lentiviral vector harboring the human β2-microglobulin promoter, with predominant expression in immune cells and minimal proximal enhancers to improve vector safety. This lentiviral vector efficiently transduces major dendritic cell subsets in vivo. With a mycobacterial immunogen, we observed distinct functional signatures and memory phenotype in lentiviral vector- or Adenovirus type 5 (Ad5)-immunized mice, despite comparable antigen-specific CD8 T cell magnitudes. Compared to Ad5, lentiviral vector immunization resulted in higher multifunctional and IL-2-producing CD8 T cells. Furthermore, lentiviral vector immunization primed CD8 T cells towards central memory phenotype, while Ad5 immunization favored effector memory phenotype. Studies using HIV antigens in outbred rats demonstrated additional clear-cut evidence for an immunogenic advantage of lentiviral vector over Ad5. Additionally, lentiviral vector provided enhance therapeutic anti-tumor protection than Ad5. In conclusion, coupling lentiviral vector with β2-microglobulin promoter represents a promising approach to produce long-lasting, high-quality cellular immunity for vaccinal purposes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lorenzo Canti</style></author><author><style face="normal" font="default" size="100%">Sophie Servais</style></author><author><style face="normal" font="default" size="100%">Grégory Ehx</style></author><author><style face="normal" font="default" size="100%">Yves Beguin</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stéphanie Humblet-Baron</style></author><author><style face="normal" font="default" size="100%">Julika Neumann</style></author><author><style face="normal" font="default" size="100%">Adrian Liston</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Heyndrickx, Leo</style></author><author><style face="normal" font="default" size="100%">Aurélie Henry</style></author><author><style face="normal" font="default" size="100%">Evelyne Willems</style></author><author><style face="normal" font="default" size="100%">Stanislas Goriely</style></author><author><style face="normal" font="default" size="100%">Laurence Seidel</style></author><author><style face="normal" font="default" size="100%">Johan Michiels</style></author><author><style face="normal" font="default" size="100%">Betty Willems</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">Arnaud Marchant</style></author><author><style face="normal" font="default" size="100%">Frédéric Baron</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.</style></title><secondary-title><style face="normal" font="default" size="100%">J Hematol Oncol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Neutralizing</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation Conditioning</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation Immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation, Homologous</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Oct 24</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Factors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain to be elucidated.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Forty allo-HCT recipients were included in a study of immunization with BNT162b2 mRNA vaccine at days 0 and 21. Binding antibodies (Ab) to SARS-CoV-2 receptor binding domain (RBD) were assessed at days 0, 21, 28, and 49 while neutralizing Ab against SARS-CoV-2 wild type (NT50) were assessed at days 0 and 49. Results observed in allo-HCT patients were compared to those obtained in 40 healthy adults naive of SARS-CoV-2 infection. Flow cytometry analysis of peripheral blood cells was performed before vaccination to identify potential predictors of Ab responses.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Three patients had detectable anti-RBD Ab before vaccination. Among the 37 SARS-CoV-2 naive patients, 20 (54%) and 32 (86%) patients had detectable anti-RBD Ab 21&amp;nbsp;days and 49&amp;nbsp;days postvaccination. Comparing anti-RBD Ab levels in allo-HCT recipients and healthy adults, we observed significantly lower anti-RBD Ab levels in allo-HCT recipients at days 21, 28 and 49. Further, 49% of allo-HCT patients versus 88% of healthy adults had detectable NT50 Ab at day 49 while allo-HCT recipients had significantly lower NT50 Ab titers than healthy adults (P = 0.0004). Ongoing moderate/severe chronic GVHD (P &amp;lt; 0.01) as well as rituximab administration in the year prior to vaccination (P &amp;lt; 0.05) correlated with low anti-RBD and NT50 Ab titers at 49&amp;nbsp;days after the first vaccination in multivariate analyses. Compared to healthy adults, allo-HCT patients without chronic GVHD or rituximab therapy had comparable anti-RBD Ab levels and NT50 Ab titers at day 49. Flow cytometry analyses before vaccination indicated that Ab responses in allo-HCT patients were strongly correlated with the number of memory B cells and of naive CD4 T cells (r &amp;gt; 0.5, P &amp;lt; 0.01) and more weakly with the number of follicular helper T cells (r = 0.4, P = 0.01).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Chronic GVHD and rituximab administration in allo-HCT recipients are associated with reduced Ab responses to BNT162b2 vaccination. Immunological markers could help identify allo-HCT patients at risk of poor Ab response to mRNA vaccination.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;TRIAL REGISTRATION: &lt;/b&gt;The study was registered at clinicaltrialsregister.eu on 11 March 2021 (EudractCT # 2021-000673-83).&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pauline Percier</style></author><author><style face="normal" font="default" size="100%">De Prins, Sofie</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Tima, Giresse</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Beyaert, Rudi</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Grooten, Johan</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Recognition by Dendritic Cells Negatively Regulates Allergic Lung Inflammation through a TLR2/MyD88 Pathway.</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Respir Cell Mol Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Aspergillus fumigatus</style></keyword><keyword><style  face="normal" font="default" size="100%">Asthma</style></keyword><keyword><style  face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Cladosporium</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Eosinophils</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Lectins, C-Type</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">Myeloid Differentiation Factor 88</style></keyword><keyword><style  face="normal" font="default" size="100%">Pulmonary Eosinophilia</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Th2 Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Toll-Like Receptor 2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">64</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;is an opportunistic fungal pathogen responsible for a spectrum of clinical manifestations. Dendritic cells recognize pathogen-associated molecular patterns of via two main receptor families, Toll-like receptors (TLRs) and C-type lectin receptors (CLR). Here, the importance of TLR and CLR signaling in the regulation of T-helper cell type 2 (Th2) responses was analyzed using a mouse model based on the transfer of bone marrow-derived dendritic cells (BMDCs) pulsed with conidia. BMDCs were generated from mice deficient in either MyD88 or MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1). Both the MyD88 and MALT1 signaling pathway in BMDCs contributed to the production of inflammatory cytokines induced by conidia. Mice sensitized with MyD88 BMDCs pulsed with conidia showed an exacerbated allergic inflammation, with stronger eosinophil recruitment in the BAL and higher Th2 cytokine production compared with mice sensitized with wild-type or MALT1 BMDCs. This exacerbation was not observed when MyD88 BMDCs were pulsed with , a nonpathogenic mold. A lack of TLR2 signaling recapitulated the exacerbation of the Th2 response observed in the absence of MyD88 signaling, whereas TLR2 agonist dampened the response induced with and conidia. IL-10 production by BMDCs in response to was dependent on the expression of TLR2 and MyD88. IL-10 BMDCs exacerbated, whereas MyD88 BMDCs supplemented with exogenous IL-10 decreased the allergic pulmonary inflammation. These results indicate that TLR2/MyD88-specific recognition of PAMPs from conidia can upregulate IL-10 production and downregulate lung eosinophilia and the development of a Th2 response.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M Peeters</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">L Verbruggen</style></author><author><style face="normal" font="default" size="100%">L Teuwen</style></author><author><style face="normal" font="default" size="100%">G Vanhoutte</style></author><author><style face="normal" font="default" size="100%">S Raats</style></author><author><style face="normal" font="default" size="100%">Isolde Van der Massen</style></author><author><style face="normal" font="default" size="100%">Sigrid C.J. De Keersmaecker</style></author><author><style face="normal" font="default" size="100%">Y Debie</style></author><author><style face="normal" font="default" size="100%">S Anguille</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">S Vande Kerckhove</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">B Peeters</style></author><author><style face="normal" font="default" size="100%">M Huizing</style></author><author><style face="normal" font="default" size="100%">Pieter Pannus</style></author><author><style face="normal" font="default" size="100%">K Neven</style></author><author><style face="normal" font="default" size="100%">K K Ariën</style></author><author><style face="normal" font="default" size="100%">G. A. Martens</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">E Roelant</style></author><author><style face="normal" font="default" size="100%">Maria Goossens</style></author><author><style face="normal" font="default" size="100%">T Vandamme</style></author><author><style face="normal" font="default" size="100%">P van Dam</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.</style></title><secondary-title><style face="normal" font="default" size="100%">ESMO Open</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Humoral</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Cancer patients are at a higher risk of developing severe coronavirus disease 2019 (COVID-19). However, the safety and efficacy of COVID-19 vaccination in cancer patients undergoing treatment remain unclear.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;PATIENTS AND METHODS: &lt;/b&gt;In this interventional prospective multicohort study, priming and booster doses of the BNT162b2 COVID-19 vaccine were administered 21 days apart to solid tumor patients receiving chemotherapy, immunotherapy, targeted or hormonal therapy, and patients with a hematologic malignancy receiving rituximab or after allogeneic hematopoietic stem cell transplantation. Vaccine safety and efficacy (until 3 months post-booster) were assessed. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) antibody levels were followed over time (until 28 days after the booster) and in&amp;nbsp;vitro SARS-CoV-2 50% neutralization titers (NT50) toward the wild-type Wuhan strain were analyzed 28 days after the booster.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Local and systemic adverse events (AEs) were mostly mild to moderate (only 1%-3% of patients experienced severe AEs). Local, but not systemic, AEs occurred more frequently after the booster dose. Twenty-eight days after the booster vaccination of 197 cancer patients, RBD-binding antibody titers and NT50 were lower in the chemotherapy group {234.05 IU/ml [95% confidence interval (CI) 122.10-448.66] and 24.54 (95% CI 14.50-41.52), respectively} compared with healthy individuals [1844.93 IU/ml (95% CI 1383.57-2460.14) and 122.63 (95% CI 76.85-195.67), respectively], irrespective of timing of vaccination during chemotherapy cycles. Extremely low antibody responses were seen in hematology patients receiving rituximab; only two patients had RBD-binding antibody titers necessary for 50% protection against symptomatic SARS-CoV-2 infection (&amp;lt;200 IU/ml) and only one had NT50 above the limit of detection. During the study period, five cancer patients tested positive for SARS-CoV-2 infection, including a case of severe COVID-19 in a patient receiving rituximab, resulting in a 2-week hospital admission.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;The BNT162b2 vaccine is well-tolerated in cancer patients under active treatment. However, the antibody response of immunized cancer patients was delayed and diminished, mainly in patients receiving chemotherapy or rituximab, resulting in breakthrough infections.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Freya Van Houtte</style></author><author><style face="normal" font="default" size="100%">Philip Meuleman</style></author><author><style face="normal" font="default" size="100%">Geert Leroux-Roels</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">Van Vlierberghe, Hans</style></author><author><style face="normal" font="default" size="100%">André Elewaut</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Ali Farhoudi</style></author><author><style face="normal" font="default" size="100%">Lieven Verhoye</style></author><author><style face="normal" font="default" size="100%">Caroline Buysschaert</style></author><author><style face="normal" font="default" size="100%">Yvonne Gijbels</style></author><author><style face="normal" font="default" size="100%">Sibyl Couvent</style></author><author><style face="normal" font="default" size="100%">Wilfried Swinnen</style></author><author><style face="normal" font="default" size="100%">Andrea Magri</style></author><author><style face="normal" font="default" size="100%">Zania Stamataki</style></author><author><style face="normal" font="default" size="100%">Jane A McKeating</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">A Role for B Cells to Transmit Hepatitis C Virus Infection.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Immunol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">B-Lymphocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">Broadly Neutralizing Antibodies</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepacivirus</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Liver</style></keyword><keyword><style  face="normal" font="default" size="100%">Liver Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">serum</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation Chimera</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Development</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Envelope Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Hepatitis Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Young adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Hepatitis C virus (HCV) is highly variable and transmits through infected blood to establish a chronic liver infection in the majority of patients. Our knowledge on the infectivity of clinical HCV strains is hampered by the lack of cell culture systems that support efficient viral replication. We and others have reported that HCV can associate with and infect immune cells and may thereby evade host immune surveillance and elimination. To evaluate whether B cells play a role in HCV transmission, we assessed the ability of B cells and sera from recent (&amp;lt;2 years) or chronic (≥ 2 years) HCV patients to infect humanized liver chimeric mice. HCV was transmitted by B cells from chronic infected patients whereas the sera were non-infectious. In contrast, B cells from recently infected patients failed to transmit HCV to the mice, whereas all serum samples were infectious. We observed an association between circulating anti-glycoprotein E1E2 antibodies and B cell HCV transmission. Taken together, our studies provide evidence for HCV transmission by B cells, findings that have clinical implications for prophylactic and therapeutic antibody-based vaccine design.&lt;/p&gt;
</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lise Boey</style></author><author><style face="normal" font="default" size="100%">Eline Bosmans</style></author><author><style face="normal" font="default" size="100%">Liane Braz Ferreira</style></author><author><style face="normal" font="default" size="100%">Nathalie Heyvaert</style></author><author><style face="normal" font="default" size="100%">Melissa Nelen</style></author><author><style face="normal" font="default" size="100%">Lisa Smans</style></author><author><style face="normal" font="default" size="100%">Hanne Tuerlinckx</style></author><author><style face="normal" font="default" size="100%">Vandermeulen, Corinne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Mathieu Roelants</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Kathleen Claes</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Derdelinckx, Inge</style></author><author><style face="normal" font="default" size="100%">Wim Janssens</style></author><author><style face="normal" font="default" size="100%">Mathieu, Chantal</style></author><author><style face="normal" font="default" size="100%">Johan Van Cleemput</style></author><author><style face="normal" font="default" size="100%">Robin Vos</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines (Basel)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jan 04</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Patients with chronic diseases are at increased risk of complications following infection. It remains, however, unknown to what extend they are protected against vaccine-preventable diseases. We assessed seroprevalence of antibodies against diphtheria, tetanus and pertussis to evaluate whether current vaccination programs in Belgium are adequate. Antibody titers were assessed with a bead-based multiplex assay in serum of 1052 adults with chronic diseases. We included patients with diabetes mellitus type 1 (DM1) ( = 172), DM2 ( = 77), chronic kidney disease ( = 130), chronic obstructive pulmonary disease (COPD) ( = 170), heart failure ( = 77), HIV ( = 196) and solid organ transplant (SOT) recipients ( = 230). Factors associated with seroprevalence were analysed with multiple logistic regression. We found seroprotective titers in 29% for diphtheria (≥0.1 IU/mL), in 83% for tetanus (≥0.1 IU/mL) and 22% had antibodies against pertussis (≥5 IU/mL). Seroprotection rates were higher ( &amp;lt; 0.001) when vaccinated within the last ten years. Furthermore, diphtheria seroprotection decreased with age ( &amp;lt; 0.001). Tetanus seroprotection was less reached in women ( &amp;lt; 0.001) and older age groups ( &amp;lt; 0.001). For pertussis, women had more often a titer suggestive of a recent infection or vaccination (≥100 IU/mL, &amp;lt; 0.01). We conclude that except for tetanus, the vast majority of at-risk patients remains susceptible to vaccine-preventable diseases such as diphtheria and pertussis.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">L Subissi</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Rodeghiero, C</style></author><author><style face="normal" font="default" size="100%">Huygen, K</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Martini, H</style></author><author><style face="normal" font="default" size="100%">Piérard, D</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Amber Litzroth</style></author><author><style face="normal" font="default" size="100%">G Leroux-Roels</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessment of IgA anti-PT and IgG anti-ACT reflex testing to improve Bordetella pertussis serodiagnosis in recently vaccinated subjects.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Microbiol Infect</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADOLESCENT</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Age factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Antibodies, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Antigens, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Bordetella pertussis</style></keyword><keyword><style  face="normal" font="default" size="100%">Child</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin A</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunoglobulin G</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Pertussis Toxin</style></keyword><keyword><style  face="normal" font="default" size="100%">Pertussis Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Serologic Tests</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">Whooping Cough</style></keyword><keyword><style  face="normal" font="default" size="100%">Young adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">26</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;Quantifying IgG antibodies to pertussis toxin (PT) is the most specific and sensitive method for the serodiagnosis of a Bordetella pertussis infection. Since PT is a component of acellular pertussis vaccines, anti-PT IgG is also induced by vaccination, precluding pertussis serodiagnosis based exclusively on anti-PT IgG in recently vaccinated subjects. Here, we aim to identify additional B.&amp;nbsp;pertussis-specific serological markers that can discriminate between infection and recent vaccination.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;The clinical usefulness of measuring IgA directed to the vaccine antigen PT and IgG directed to non-vaccine antigens (Fim2/3, LPS, ACT, CatACT) was evaluated in nine well characterized subject groups, aged 10-89&amp;nbsp;years (n&amp;nbsp;=&amp;nbsp;390). Serum anti-PT IgG levels (&amp;gt;125 IU/mL) served as an indicator for a recent B.&amp;nbsp;pertussis infection. Comparing symptomatic pertussis-infected subjects (n&amp;nbsp;=&amp;nbsp;140) with recently vaccinated, non-infected subjects (n&amp;nbsp;=&amp;nbsp;100) revealed the optimal cut-off, accuracy, sensitivity and specificity for each single parameter.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;For pertussis diagnosis in recently vaccinated subjects, the measurement of anti-PT IgA (cut-off 15 IU/mL) and anti-ACT IgG (cut-off 15 U/mL) resulted in accuracies of 95% (91.5-97.1) and 87.5% (82.7-91.1), sensitivities of 92.9% (87.4-96.0) and 83.6% (76.5-88.8) and specificities of 98% (93.0-99.4) and 93% (86.3-96.6), respectively. Comparing anti-PT IgA levels between the youngest (10-19&amp;nbsp;years, n&amp;nbsp;=&amp;nbsp;38) and oldest (70-89&amp;nbsp;years, n&amp;nbsp;=&amp;nbsp;17) age groups revealed an age-dependent increase in antibody levels in pertussis-infected subjects (p&amp;nbsp;&amp;lt;&amp;nbsp;0.0001).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Reflex testing of anti-PT IgA and anti-ACT IgG improves pertussis serodiagnosis in recently vaccinated symptomatic subjects with elevated anti-PT IgG levels. Furthermore, both markers can discriminate between vaccination and recent infection in pertussis serosurveillance studies.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Timothy Devos</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">Tatjana Geukens</style></author><author><style face="normal" font="default" size="100%">Myriam Cleeren</style></author><author><style face="normal" font="default" size="100%">Peter Verhamme</style></author><author><style face="normal" font="default" size="100%">Geert Meyfroidt</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Alexander Schauwvlieghe</style></author><author><style face="normal" font="default" size="100%">Ariën, Kevin K</style></author><author><style face="normal" font="default" size="100%">Cyril Barbezange</style></author><author><style face="normal" font="default" size="100%">Veerle Compernolle</style></author><author><style face="normal" font="default" size="100%">Nicolas Dauby</style></author><author><style face="normal" font="default" size="100%">Desmecht, Daniel</style></author><author><style face="normal" font="default" size="100%">David Grimaldi</style></author><author><style face="normal" font="default" size="100%">Bart N Lambrecht</style></author><author><style face="normal" font="default" size="100%">Anne Luyten</style></author><author><style face="normal" font="default" size="100%">Piet Maes</style></author><author><style face="normal" font="default" size="100%">Moutschen, Michel</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Lucie Seyler</style></author><author><style face="normal" font="default" size="100%">Michel Toungouz Nevessignsky</style></author><author><style face="normal" font="default" size="100%">Katleen Vandenberghe</style></author><author><style face="normal" font="default" size="100%">Johan van Griensven</style></author><author><style face="normal" font="default" size="100%">Verbeke, Geert</style></author><author><style face="normal" font="default" size="100%">Vlieghe, Erika</style></author><author><style face="normal" font="default" size="100%">Jean Cyr Yombi</style></author><author><style face="normal" font="default" size="100%">Laurens Liesenborghs</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of valescent plasma to the standard of care in patients hospitalized with COVID- nCoV (DAWn-Plasma) trial.</style></title><secondary-title><style face="normal" font="default" size="100%">Trials</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 Dec 14</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">21</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Faith Osier</style></author></authors><tertiary-authors><author><style face="normal" font="default" size="100%">Jenny P Y Ting</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">John Fraser</style></author><author><style face="normal" font="default" size="100%">Bart N Lambrecht</style></author><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Ricardo T Gazzinelli</style></author><author><style face="normal" font="default" size="100%">Karina R Bortoluci</style></author><author><style face="normal" font="default" size="100%">Dario S Zamboni</style></author><author><style face="normal" font="default" size="100%">Arne N Akbar</style></author><author><style face="normal" font="default" size="100%">Jennie Evans</style></author><author><style face="normal" font="default" size="100%">Doug E Brown</style></author><author><style face="normal" font="default" size="100%">Kamala D Patel</style></author><author><style face="normal" font="default" size="100%">Wu, Yuzhang</style></author><author><style face="normal" font="default" size="100%">Ana B Perez</style></author><author><style face="normal" font="default" size="100%">Oliver Pérez</style></author><author><style face="normal" font="default" size="100%">Thomas Kamradt</style></author><author><style face="normal" font="default" size="100%">Christine Falk</style></author><author><style face="normal" font="default" size="100%">Mira Barda-Saad</style></author><author><style face="normal" font="default" size="100%">Ariel, Amiram</style></author><author><style face="normal" font="default" size="100%">Angela Santoni</style></author><author><style face="normal" font="default" size="100%">Francesco Annunziato</style></author><author><style face="normal" font="default" size="100%">Marco A Cassatella</style></author><author><style face="normal" font="default" size="100%">Hiroshi Kiyono</style></author><author><style face="normal" font="default" size="100%">Valeriy Chereshnev</style></author><author><style face="normal" font="default" size="100%">Alioune Dieye</style></author><author><style face="normal" font="default" size="100%">Moustapha Mbow</style></author><author><style face="normal" font="default" size="100%">Babacar Mbengue</style></author><author><style face="normal" font="default" size="100%">Maguette D S Niang</style></author><author><style face="normal" font="default" size="100%">Melinda Suchard</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The global response to the COVID-19 pandemic: how have immunology societies contributed?</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Rev Immunol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antiviral Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Betacoronavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">Community-Institutional Relations</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronavirus Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Global Health</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">International Cooperation</style></keyword><keyword><style  face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient Education as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Personal Protective Equipment</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Severe Acute Respiratory Syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">Societies, Scientific</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Vaccines</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The COVID-19 pandemic is shining a spotlight on the field of immunology like never before. To appreciate the diverse ways in which immunologists have contributed, Nature Reviews Immunology invited the president of the International Union of Immunological Societies and the presidents of 15 other national immunology societies to discuss how they and their members responded following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maud Deny</style></author><author><style face="normal" font="default" size="100%">Georges Casimir</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Marta Romano</style></author><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author></secondary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Mustapha Chamekh</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Progressive Control of Streptococcus agalactiae-Induced Innate Inflammatory Response Is Associated with Time Course Expression of MicroRNA-223 by Neutrophils.</style></title><secondary-title><style face="normal" font="default" size="100%">Infect Immun</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemokine CXCL1</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemokine CXCL2</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-1beta</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">MicroRNAs</style></keyword><keyword><style  face="normal" font="default" size="100%">Monocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">Neutrophils</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia</style></keyword><keyword><style  face="normal" font="default" size="100%">Streptococcus agalactiae</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 Nov 16</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">88</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Group B streptococcus (GBS) is a human-pathogenic bacterium inducing a strong inflammatory response that may be detrimental for host tissues if not finely regulated. The inflammatory response can be modulated by different molecular mechanisms, among which growing evidence points toward the crucial role of microRNAs (miRNAs). Regarding innate inflammatory response, studies have reported that miR-223 is essential for the control of granulocyte proliferation and activation. Moreover, a number of investigations on miRNA expression profiling performed in various inflammatory settings have revealed that miR-223 is among the top differentially expressed miRNAs. Yet the dynamic pattern of expression of miR-223 with respect to the evolution of the inflammatory process, especially in microbial infection, remains elusive. In this study, we analyzed the kinetic expression of miR-223 in an inflammatory model of GBS-induced murine pneumonia and looked for correlates with inflammatory markers, including innate cell infiltrates. We found that miR-223 expression is rapidly induced at very early time points (3 to 6 h postinfection [p.i.]) mainly by lung-infiltrating neutrophils. Interestingly, the level of miR-223 accumulating in the lungs remains higher at later stages of infection (24 h and 48 h p.i.), and this correlates with reduced expression of primary inflammatory cytokines and chemokines and with a shift in infiltrating monocyte and macrophage subtypes toward a regulatory phenotype. Transient inhibition of miR-223 by an antagomir resulted in significant increase of CXCL2 expression and partial enhancement of infiltrating neutrophils in GBS-infected lung tissues. This suggests the potential contribution of miR-223 to the resolution phase of GBS-induced acute inflammation.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helena Martini</style></author><author><style face="normal" font="default" size="100%">Oriane Soetens</style></author><author><style face="normal" font="default" size="100%">Ingrid Wybo</style></author><author><style face="normal" font="default" size="100%">Piérard, Denis</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">David Litt</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Norman K Fry</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Liselot Detemmerman</style></author><author><style face="normal" font="default" size="100%">I Desombere</style></author><author><style face="normal" font="default" size="100%">Androulla Efstratiou</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Diphtheria in Belgium: 2010-2017.</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Microbiol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">ADOLESCENT</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">Corynebacterium</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphtheria Toxin</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">middle aged</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">68</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In Western Europe, the incidence of both respiratory and cutaneous diphtheria, caused by toxin-producing , or , has been low over the past few decades thanks to the use of an effective vaccine and a high level of vaccination coverage. However, the disease has still not been eradicated and continues to occur in all of Europe. In order to prevent sequelae or a fatal outcome, diphtheria antitoxin (DAT) should be administered to suspected diphtheria patients as soon as possible, but economic factors and issues concerning regulations have led to poor availability of DAT in many countries. The European Centre for Disease Prevention and Control and World Health Organization have called for European Union-wide solutions to this DAT-shortage. In order to illustrate the importance of these efforts and underline the need for continued diphtheria surveillance, we present data on all registered cases of toxigenic and non-toxigenic , and in Belgium during the past decade, up to and including 2017.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chu, Ha Thi</style></author><author><style face="normal" font="default" size="100%">Nguyen Huu Lan</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Virginie Doyen</style></author><author><style face="normal" font="default" size="100%">Michel, Olivier</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Tran, Thanh Ngoc</style></author><author><style face="normal" font="default" size="100%">Ngo, Minh Xuan</style></author><author><style face="normal" font="default" size="100%">Tran Thi Mong Hiep</style></author></tertiary-authors><subsidiary-authors><author><style face="normal" font="default" size="100%">Denis, Olivier</style></author><author><style face="normal" font="default" size="100%">Tran, Thi Thu Thuy</style></author><author><style face="normal" font="default" size="100%">Diem Nguyen Thi Kieu</style></author><author><style face="normal" font="default" size="100%">Francis Corazza</style></author><author><style face="normal" font="default" size="100%">Bouland, Catherine</style></author><author><style face="normal" font="default" size="100%">Jean-Marie Hauglustaine</style></author><author><style face="normal" font="default" size="100%">Isabelle Godin</style></author></subsidiary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The protective effect of rural life on mite sensitization disappears among urban migrants in the South of Vietnam.</style></title><secondary-title><style face="normal" font="default" size="100%">World Allergy Organ J</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Rapid urbanization combined with rural migration to urban areas in southern Vietnam could be risk factors for allergen sensitization, contributing to chronic respiratory diseases (CRD). We aimed to evaluate the prevalence of mite sensitization and its relation to house dust characteristics among rural and urban native and migrating populations with CRD.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Rural (n&amp;nbsp;=&amp;nbsp;19) and urban (n&amp;nbsp;=&amp;nbsp;46) dwellings were defined on the basis of a home typology. Controls were western Belgian houses (n&amp;nbsp;=&amp;nbsp;14). Besides the house characteristics, both endotoxin and mite allergens were measured in the settled dusts. The sensitization to mite allergens was defined by positive skin prick test (SPT) and concentration of specific IgE (sIgE)≥ 0.7 U/mL. The prevalence of mite sensitization was evaluated among 610 patients with CRD and compared according to both their home types and places of birth and residences.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The concentration of endotoxin (but not mite allergen) was higher in rural compared to urban dusts (440 (95%CI: 314-566) versus 170 (95%CI: 115-226) EU/mg; p&amp;nbsp;&amp;lt;&amp;nbsp;0.0001). The prevalence of positive sIgE to Der p1 and Der p2 was significantly lower in rural (9% and 5%) compared to urban (15% and 9%) population, consistent with the positive SPT to mite (14% and 21%, respectively). Among the urban migrants, the risk of mite sensitization (SPT) was higher compared to the rural natives (OR: 1.79 (1.02-3.15), p&amp;nbsp;&amp;lt;&amp;nbsp;0.05) and not different to the urban ones (OR: 1.35 (0.82-2.23) p NS).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;In Vietnam, associated with higher endotoxin (but not allergen) dust concentrations, the risk of mite sensitization was lower in rural compared to the native urban population, but this protective effect could disappear among rural to urban migrants.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bavo Verhaegen</style></author><author><style face="normal" font="default" size="100%">Alexandra Vodolazkaia</style></author><author><style face="normal" font="default" size="100%">Marina Mukovnikova</style></author><author><style face="normal" font="default" size="100%">Katelijne Dierick</style></author><author><style face="normal" font="default" size="100%">Koenraad Van Hoorde</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular characterization of human pathogenic norovirus circulating in Belgium: 10 years of systematic molecular surveillance data</style></title></titles><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>13</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Inne Nauwelaers</style></author><author><style face="normal" font="default" size="100%">E. Cornelissen</style></author><author><style face="normal" font="default" size="100%">M. Lapaille</style></author><author><style face="normal" font="default" size="100%">M. Abady</style></author><author><style face="normal" font="default" size="100%">Hubschen,J.M.</style></author><author><style face="normal" font="default" size="100%">Alexandra Vodolazkaia</style></author><author><style face="normal" font="default" size="100%">Marina Mukovnikova</style></author><author><style face="normal" font="default" size="100%">Steven Van Gucht</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Positive rubella sample in Belgium after vaccination of 15-month-old child</style></title></titles><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>